Central nervous system disorders are sometimes triggered by an underlying cancer. In this test-specific episode of the "Answers From the Lab" podcast, Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 autoantibody tests facilitate early diagnosis and treatment of these disabling paraneoplastic neurological syndromes.

Several antibodies are associated with paraneoplastic neurological syndromes. Assays for two of these antibodies — PDE10A and TRIM46 — are available only through Mayo Clinic Laboratories. Both will be included in most of Mayo Clinic's central nervous system panels. These antibodies have been reported among patients with immune checkpoint inhibitor-associated central nervous system adverse events, especially movement disorders such as ataxia (TRIM46) or hyperkinetic involuntary movements (PDE10A). 

"The goal for patients with paraneoplastic neurological syndromes is the earliest possible diagnosis so we can limit the extent of neuronal injury or loss," Dr. Dubey says. "That highlights the importance of utilizing these antibodies in our panels for early initiation of treatment."

The PDE10A antibody was discovered at Mayo Clinic and is often associated with renal cell or lung cancer. TRIM46 is associated with neuroendocrine tumors. "These antibodies are going to help not only with the diagnosis of these patients but also to guide the search for underlying tumor types," Dr. Dubey says.

Listen to learn more about Mayo Clinic Laboratories' PDE10A and TRIM46 testing.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ENC2 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

ENS2 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

MAS1 | Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum

MDC2 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

MDS2 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less